COSCIENS Biopharma 

COSCIENS Biopharma Inc. is a specialized biopharmaceutical company dedicated to the global development and commercialization of innovative therapeutic and diagnostic products. Its operations extend across Canada, Switzerland, Ireland, Denmark, Germany, the United States, and other international territories. The company's flagship product is Macrilen (macimorelin), an orally administered peptidomimetic ghrelin receptor (GHSR-1a) agonist. This compound works by stimulating growth hormone secretion through its interaction with the GHSR-1a receptor, primarily serving for the diagnosis of both adult and childhood-onset growth hormone deficiency. It also shows promise in other endocrinology and oncology applications. Its pipeline includes AEZS-150, a delayed-clearance parathyroid hormone fusion polypeptide currently undergoing preclinical evaluation for the management of chronic hypoparathyroidism. Another preclinical candidate, AEZS-130, is being investigated for its potential in treating amyotrophic lateral sclerosis (ALS). COSCIENS has established a license and research collaboration with the University of Wuerzburg. This partnership aims to develop, produce, and market AIM biologicals targeting neuromyelitis optica spectrum disorder, alongside conducting preclinical research into their potential for Parkinson's disease treatment. To further its commercial efforts for Macrilen, the company has licensing agreements with Consilient Health Ltd. and NK MEDITECH Ltd. for its development and commercialization, as well as a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood specifically for Macrilen's diagnostic application in pediatric and adult growth hormone deficiency. Further collaborations include an agreement with The University of Sheffield in the United Kingdom, focused on the development, manufacturing, and commercialization of parathyroid hormone fusion polypeptides designed to address chronic hypoparathyroidism. Originally incorporated in 1990 as Aeterna Zentaris Inc., the company officially rebranded as COSCIENS Biopharma Inc. in August 2024. Its corporate headquarters are located in Toronto, Canada.